Clinical Trial Update: Systemic Vascular Endothelial Growth Factor (VEGF) Protein Dynamics Following Intravitreal Injections of Ranibizumab Versus Aflibercept in Patients With Neovascular Age-related Macular Degeneration [Phase 4]

View source ↗

Summary

Phase 4 trial comparing systemic VEGF protein dynamics after intravitreal ranibizumab versus aflibercept in wet age-related macular degeneration; results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Wet Age-related Macular Degeneration

Drugs mentioned

• Aflibercept (Aflibercept)
• Ranibizumab (ranibizumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Wet Age-Related Macular Degeneration | Phase 4 | Status: COMPLETED | Results posted: 2019-05-07